Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GNLX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Olvimulogene Nanivacirepvec | Platinum-resistant Ovarian Cancer | Phase 3 · NCT05281471 | Recruiting |
| Platinum chemotherapy: carboplatin (preferred)… | Platinum-resistant Ovarian Cancer | Phase 3 · NCT05281471 | Recruiting |
| Non-platinum chemotherapy: paclitaxel or… | Advanced Non-squamous Non-small-cell Lung Cancer | Phase 2 · NCT06463665 | Recruiting |
| Platinum | SCLC, Extensive Stage | Phase 1/2 · NCT07136285 | Recruiting |
| Platinum-doublet with or without bevacizumab | Ovarian Cancer | Phase 1/2 · NCT02759588 | Completed |
Also used in these trials (approved or third-party drugs, not GNLX's own candidates): Bevacizumab, Docetaxel Anhydrous, Etoposide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GNLX holds $18.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.3M/quarter from operations, an estimated runway of 9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 94 · High
These factors raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GNLX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Aladar Szalay | 5%+ holder (13G) | 2,834,465 | 5.90% | 2026-09-30 |
| Woodward Diversified Capital, LLC | Institution (13F) | 2,262,108 | 4.71% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 1,677,724 | 3.49% | 2026-06-30 |
| Thomas Zindrick President and CEO · +1.83M options |
Insider | 1,423,338 | 2.96% | 2026-11-03 |
| Bleichroeder LP | Institution (13F) | 1,380,666 | 2.87% | 2026-06-30 |
| John Thomas Director · +60,142 options |
Insider | 501,193 | 1.04% | 2026-06-16 |
| Blackrock Inc. | Institution (13F) | 439,602 | 0.91% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 439,213 | 0.91% | 2026-06-30 |
| CM Management, LLC | Institution (13F) | 400,000 | 0.83% | 2026-06-30 |
| Bank of America Corporation | Institution (13F) | 328,803 | 0.68% | 2026-06-30 |
| Joseph Cappello Chief Technical Officer · +174,999 options |
Insider | 317,812 | 0.66% | 2026-11-03 |
| Matthew Pulisic Chief Financial Officer |
Insider | 278,906 | 0.58% | 2026-06-16 |
Share count 48,064,184 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-31 filed 2026-09-02 |
Zindrick Thomas |
Sale (S) | 34,463 | $2.67 | 1,226,427 |
| 2026-08-31 filed 2026-09-02 |
Yu Yong |
Sale (S) | 9,683 | $2.75 | 258,688 |
| 2026-08-31 filed 2026-09-02 |
Cappello Joseph |
Sale (S) | 10,257 | $2.74 | 318,480 |
| 2026-08-04 filed 2026-08-04 |
Yu Yong |
Sale (S) | 653 | $2.94 | 268,371 |
| 2026-08-04 filed 2026-08-04 |
Cappello Joseph |
Sale (S) | 653 | $2.95 | 328,737 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GNLX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →